Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
Mark G ThompsonJefferey L BurgessAllison L NalewayHarmony TynerSarang K YoonJennifer MeeceLauren E W OlshoAlberto J Caban-MartinezAshley L FowlkesKaren LutrickHolly C GroomKayan DunniganMarilyn J OdeanKurt HegmannElisha StefanskiLaura J EdwardsNatasha Schaefer-SolleLauren GrantKatherine EllingsonJennifer L KuntzTnelda ZunieMatthew S ThieseLynn IvacicMeredith G WesleyJulie Mayo LamberteXiaoxiao SunMichael E SmithAndrew L PhillipsKimberly D GrooverYoung M YooJoseph GeraldRachel T BrownMeghan K HerringGregory JosephShawn BeitelTyler C MorrillJosephine MakPatrick RiversBrandon P PoeBrian LynchYingtao ZhouJing ZhangAnna KelleherYan LiMonica DickersonErika HansonKyley GuentherSuxiang TongAllen BatemanErik ReisdorfJohn BarnesEduardo Azziz-BaumgartnerDanielle R HuntMelissa L ArvayPreeta KuttyAlicia M FryManjusha GaglaniPublished in: The New England journal of medicine (2021)
Authorized mRNA vaccines were highly effective among working-age adults in preventing SARS-CoV-2 infection when administered in real-world conditions, and the vaccines attenuated the viral RNA load, risk of febrile symptoms, and duration of illness among those who had breakthrough infection despite vaccination. (Funded by the National Center for Immunization and Respiratory Diseases and the Centers for Disease Control and Prevention.).